Close

Hologic (HOLX) PT Raised to $33 at Needham & Company on Strong Q1 Growth Acceleration

January 29, 2015 8:24 AM EST
Get Alerts HOLX Hot Sheet
Price: $77.96 +0.79%

Rating Summary:
    11 Buy, 18 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE

Needham & Company analyst Mike Matson reiterated a Buy rating and boosted his price target on Hologic (NASDAQ: HOLX) to $33.00 (from $30.00) following broad-based growth acceleration in Q1.

Matson commented, "HOLX's F1Q15 revenue was consistent with its 1/12/15 preannouncement while EPS beat consensus. Management raised guidance but we believe it remains conservative with the implied growth well below what was seen in F1Q15. Encouragingly, HOLX's two problem areas (Cytology & Perinatal and NovaSure) stabilized and even grew slightly as sales execution improved. We reiterate our Buy rating and raise our price target to $33 from $30 since we expect HOLX to see further improvement in its revenue growth and to continue to beat consensus estimates during FY15."

The firm raised raised FY 2015 EPS from $1.54 to $1.57 and FY 2016 EPS from $1.63 to $1.68.

For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.

Shares of Hologic closed at $29.61 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Needham & Company